Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSkinbiotherap. Regulatory News (SBTX)

Share Price Information for Skinbiotherap. (SBTX)

Share Price is delayed by 15 minutes
Get Live Data
10.25    -0.25 (-2.38%)
Bid:
10.00
Ask:
10.50
Spread: 0.50 (5.00%)
Market Cap: £26.56m
SBTX Live PriceLast checked at - London Stock Exchange

Intraday Skinbiotherap. Share Chart

Holding(s) in Company

13 Oct 2025 15:31

RNS Number : 1594D
SkinBioTherapeutics PLC
13 October 2025
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BF33H870

Issuer Name

SKINBIOTHERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Optibiotix Health plc

City of registered office (if applicable)

York

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

10-Oct-2025

6. Date on which Issuer notified

13-Oct-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

6.410000

0.000000

6.410000

16600000

Position of previous notification (if applicable)

7.950000

0.000000

7.950000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Ordinary

16600000

0

6.410000

0.000000

Sub Total 8.A

16600000

6.410000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

13-Oct-2025

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLMJBITMTTBBIA
Date   Source Headline
29th Jun 20267:00 amRNSIMC Presentation Statement
25th Jun 202612:00 pmRNSDirectorate change
23rd Jun 202612:03 pmRNSNotice of Investor Presentation
8th Jun 20267:30 amRNSRestoration - SkinBioTherapeutics PLC
8th Jun 20267:00 amRNSHalf-year Results (HY26) and Restated FY25 Results
28th May 20267:00 amRNSUpdate on Investigation, Interims and Auditors
12th May 202610:13 amRNSHolding(s) in Company
5th May 20262:30 pmRNSHolding(s) in Company
29th Apr 20262:30 pmRNSUpdate on the FRP Investigation
1st Apr 202610:30 amRNSHolding(s) in Company
1st Apr 20267:30 amRNSSuspension - Skinbiotherapeutics plc
1st Apr 20267:00 amRNSStatement re. Suspension
20th Mar 202611:30 amRNSUpdate On Board Investigation and Interims Date
13th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20267:00 amRNSHolding(s) in Company
9th Mar 20267:00 amRNSAppointment of the Interim CEO to the Board
2nd Mar 20267:00 amRNSAppointment of Interim CEO
20th Feb 20267:00 amRNSIndependent Investigation Appointment
16th Feb 20267:00 amRNSUpdate on Board Investigation
13th Feb 20267:00 amRNSResignation of CEO
12th Feb 202611:00 amRNSHolding(s) in Company
11th Feb 20267:00 amRNSIssue of Equity and Total Voting Rights
29th Jan 20267:00 amRNSHolding(s) in Company
22nd Jan 20269:00 amRNSTotal Voting Rights
20th Jan 20267:00 amRNSHolding(s) in Company
20th Jan 20267:00 amRNSIssue of Equity and Total Voting Rights
15th Jan 20263:21 pmRNSHolding(s) in Company
7th Jan 202611:00 amRNSHolding(s) in Company
5th Jan 20267:00 amRNSDirectorate change
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
29th Dec 20252:00 pmRNSResult of AGM
29th Dec 20252:00 pmRNSResult of AGM
29th Dec 20257:00 amRNSHolding(s) in Company
29th Dec 20257:00 amRNSHolding(s) in Company
18th Dec 20257:00 amRNSReconfirmation of Market Guidance and AGM Q&A
8th Dec 20252:31 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNSPosting of Annual Report and AGM Notice
5th Dec 20257:00 amRNSFinal Results
26th Nov 20257:00 amRNSHolding(s) in Company
19th Nov 20257:00 amRNSHolding(s) in Company
4th Nov 20253:41 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSDirectorate Change
13th Oct 20253:31 pmRNSHolding(s) in Company
13th Oct 20253:30 pmRNSHolding(s) in Company
6th Oct 20257:00 amRNSSuperdrug first phase of store locations
1st Oct 20254:30 pmRNSHolding(s) in Company
14th Aug 20257:00 amRNSFY Trading Update
30th Jun 20257:00 amRNSCroda Commercial Launch Progressing as Expected
27th Jun 20257:00 amRNSNotice of IMC Shareholder Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.